Bionomics Limited (NASDAQ:BNOX) Sees Significant Decrease in Short Interest

Bionomics Limited (NASDAQ:BNOX) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 73,000 shares, a decrease of 39.4% from the September 15th total of 120,400 shares. Based on an average trading volume of 964,700 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC acquired a new stake in Bionomics Limited (NASDAQ:BNOX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent quarter. Institutional investors own 15.90% of the company’s stock.

Bionomics Stock Up 3.6 %

Shares of NASDAQ:BNOX opened at $0.28 on Friday. The stock’s 50-day moving average is $0.56 and its 200-day moving average is $0.76. Bionomics has a 52-week low of $0.25 and a 52-week high of $4.73.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Bionomics in a report on Thursday, August 1st.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.